Science Driven CRO

Science Driven CRO


Clinical Development in Challenging Cancers (04): Cholangiocarcinoma (CCA)

Click to read online

In the final installment of this four-part series on the Clinical Development in Challenging Cancers, our Medics take a closer look at the developing treatments and therapeutic challenges of Cholangiocarcinoma (CCA):

“CCA is considered to be the second most frequent primary hepatobiliary malignancy after hepatocellular carcinoma (HCC)4. Due to the uneven distribution of risk factors, incidence rates are varying intra- and intercontinentally, with the lowest rates in Australia and the highest rates in Southeast Asia, where annual incidence rates can reach up to 71.3/100,0005.”

We invite you to read the entire article (pages 40-43) in the Journal for Clinical Studies by clicking at the cover image.